Blood glucose monitoring and drug administration control device and control method based on shunt capacitor
Hydrogen peroxide is generated through reaction between the parallel capacitor group and glucose oxidase, changing the dielectric dielectric constant, and combining with the 555 clock chip, real-time monitoring of blood glucose concentration and automatic insulin administration are achieved, solving the difficulty in driving signal output in the prior art. The problem has improved the safety and operability of blood sugar monitoring and drug administration control.
Patent Information
- Application Number
- CN202411173721.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-06
AI Technical Summary
The existing blood sugar monitoring methods are difficult to achieve continuous signal output, and cannot drive automatic dosing of the drug delivery system. The dosing process lacks visualization and data feedback, which poses safety risks.
The parallel capacitor group was used to combine glucose oxidase and interstitial liquid to pass through the MoS2 nanosheet hydrogel microcapacitor, and the blood glucose concentration was monitored in real time using a 555 clock chip, and the insulin administration mechanism was controlled automatically through capacitance changes.
It realizes real-time monitoring of blood sugar concentration and automatic control of insulin administration, which is safe and convenient, simple in structure and strong operation, and can continuously monitor blood sugar and control the administration process.
Smart Images

Figure QLYQS_1 
Figure BDA0005010103800000031 
Figure BDA0005010103800000061
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of blood sugar monitoring and drug administration control, and in particular relates to a blood sugar monitoring and drug administration control device and a control method based on parallel capacitors. Background Art
[0002] How to achieve high compliance of active glucose control management for diabetic patients has always been the focus of attention in the field of chronic disease management, and improving patient compliance mainly requires reducing the pain caused by blood glucose monitoring and administration of glucose control drugs. Common methods of blood glucose monitoring include invasive monitoring methods such as fingertip blood sampling, and minimally invasive or non-invasive monitoring methods such as continuous blood glucose concentration monitoring technology (CGM), near-infrared monitoring, modified Raman method, microneedle method, etc. Since the hollow microneedle based on 3D printing can realize the function of body fluid collection and transdermal drug delivery, it can be customized according to patient needs and is a relatively popular technology at present. However, in terms of the calibration method of blood glucose monitoring, most of them are photothermal principle, colorimetric principle or reduction current measurement method during blood glucose calibration; the outputs of the first two are fluorescence intensity, grayscale value, etc., respectively. The signal output is difficult to input into the driving drug delivery control system, and the method using reduction current measurement is usually used for intermittent monitoring, which cannot realize the function of controlling drug delivery according to blood glucose concentration. In addition, some studies have achieved drug delivery through ion permeation-driven drug delivery systems. Although this method can automatically deliver drugs according to blood sugar concentration, the entire drug delivery process lacks visualization and data feedback, and the drug delivery process cannot be controlled. Patients cannot know the use of the drug solution, which poses certain risks. Therefore, when microneedle technology is applied in the field of blood sugar monitoring and drug delivery control, there is an urgent need for a device that can continuously generate signals based on blood sugar concentration and that can drive the drug delivery system to deliver drugs, thereby expanding the scope of application of microneedles. Summary of the invention
[0003] The purpose of the present invention is to overcome the deficiencies in the prior art and provide a blood glucose monitoring and drug administration control device and a control method based on parallel capacitors. The scheme is functionally divided into two parts. One part is the continuous monitoring of blood glucose concentration. The interstitial fluid extracted by glucose oxidase and hollow microneedles flows through the parallel low-doped molybdenum disulfide nanosheet hydrogel microcapacitor. Under the action of a 555 clock chip, the square wave period provided by the clock chip is changed by changing the dielectric constant of the capacitor to achieve the purpose of real-time monitoring of blood glucose concentration; the other part is a drug administration control device for a glucose-controlling liquid, which realizes automatic drug administration when the blood glucose concentration exceeds a specified range.
[0004] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:
[0005] (I) The present invention provides a blood glucose monitoring and drug administration control device based on parallel capacitors, comprising an interstitial fluid collection microneedle, an interstitial fluid injection channel, a glucose oxidase injection channel, a parallel capacitor group, an insulin drug administration mechanism and a central control unit; the parallel capacitor group comprises a connecting pipe and a plurality of parallel capacitors, the dielectric inside the capacitor is doped with MoS2 nanosheets, the capacitor is provided with a liquid inlet end and a liquid outlet end, and the connecting pipe connects the liquid inlet ends and the liquid outlet ends of the plurality of capacitors in series in sequence; the interstitial fluid injection channel is connected to the interstitial fluid collection microneedle on the one hand, and is connected to the inlet of the connecting pipe on the other hand, and the glucose oxidase injection channel is connected to the inlet of the connecting pipe; the interstitial fluid inside the interstitial fluid injection channel and the glucose oxidase inside the glucose oxidase injection channel flow into each capacitor in sequence through the connecting pipe and contact with the dielectric inside the capacitor; the central control unit is connected to the parallel capacitor group and the insulin drug administration mechanism, continuously monitors the real-time total capacitance change of the parallel capacitor group, obtains the real-time pulse width change of the central control unit chip according to the real-time total capacitance change, and then obtains the real-time blood glucose concentration, and controls the insulin drug administration mechanism to automatically administer the drug according to the real-time blood glucose concentration.
[0006] Furthermore, the insulin delivery mechanism includes an insulin reservoir, an insulin input channel, a delivery power device and a delivery microneedle; the insulin reservoir, the insulin input channel and the delivery microneedle are connected in sequence, and the delivery power device is arranged on the insulin input channel to provide delivery power under the control of the central control unit.
[0007] Furthermore, the dielectric is an electrolytic paper impregnated with a MoS2 gel, and the preparation method is: mixing and stirring a MoS2 nanosheet dispersion, polyethylene glycol and polyvinyl alcohol at room temperature and drying to form a PVA-PEG-MoS2 mixed gel, and impregnating the electrolytic paper in the mixed gel to obtain a dielectric; the mass percentage concentration of the MoS2 nanosheets in the mixed gel is not less than 2%.
[0008] Furthermore, the device is also provided with a mixing pool; the liquid outlet end of the interstitial fluid injection channel and the liquid outlet end of the glucose oxidase injection channel are respectively connected to the liquid inlet of the mixing pool, and the liquid outlet of the mixing pool is connected to the inlet of the connecting pipe. The interstitial fluid inside the interstitial fluid injection channel and the glucose oxidase inside the glucose oxidase injection channel first enter the mixing pool for mixing, and then flow into each capacitor in turn through the connecting pipe.
[0009] Furthermore, a sampling power device is provided in the mixing tank, and the power device provides power for the flow of interstitial fluid and glucose oxidase under the control of the central control unit.
[0010] Furthermore, a glucose oxidase reservoir is provided, and the glucose oxidase reservoir is connected to the glucose oxidase injection channel;
[0011] (II) The present invention provides a blood sugar monitoring and drug administration control method based on parallel capacitors, which is completed based on the above-mentioned device, and the control method includes:
[0012] S1, start the driving device, the interstitial fluid collection microneedle draws interstitial fluid from the skin and enters the interstitial fluid injection channel, and at the same time, the glucose oxidase in the glucose oxidase reservoir enters the glucose oxidase injection channel;
[0013] S2, interstitial fluid and glucose oxidase enter the parallel capacitor group, flow into each parallel capacitor in turn through the connecting pipe, and come into contact with the dielectric doped with MoS2 nanosheets in the capacitor, the dielectric constant of the dielectric changes, and thus the capacitance of the capacitor changes;
[0014] S3, the central control unit monitors the total capacitance change of the parallel capacitor group in real time, obtains the real-time pulse width change of the central control unit chip according to the real-time total capacitance change, and then obtains the real-time blood glucose concentration;
[0015] S4. When the real-time blood glucose concentration is monitored to be greater than the specified value, the central control unit controls the drug delivery power device to start, and the insulin in the insulin reservoir is automatically delivered through the insulin input channel and the drug delivery microneedle.
[0016] Furthermore, in the S2, glucose oxidase reacts with the interstitial fluid to generate hydrogen peroxide, and the hydrogen peroxide oxidizes MoS2 to generate MoO3, thereby reducing the doping amount of MoS2 in the dielectric, thereby reducing the dielectric constant of the dielectric, and thus changing the capacitance of the capacitor.
[0017] Furthermore, in S3, the relationship between the real-time blood glucose concentration and the real-time pulse width change of the central control unit chip is:
[0018]
[0019] Among them, Δt w is the real-time pulse width variation of the central control unit chip; n k is the number of capacitors consumed after the kth detection; n k-1 is the number of capacitors consumed after k-1 tests; S is the effective relative area between capacitor electrodes, which is a constant; d is the effective spacing between capacitor electrodes, which is a constant; C max is the initial capacitance value of a single capacitor; C min is the capacitance value of a single capacitor after MoS2 is depleted; K is the dielectric-mass fraction proportional coefficient of MoS2 in the dielectric; μ is the consumption coefficient between blood glucose and MoS2 in the catalytic process, which is a constant when the temperature is constant; V is the volume of interstitial fluid extracted each time; R is the equivalent resistance of the central control unit chip, which is a constant.
[0020] Furthermore, the central control unit can monitor the remaining amount of glucose oxidase in the glucose oxidase reservoir and the remaining amount of insulin in the insulin reservoir, and feed back to the client via the Bluetooth transmission module.
[0021] Beneficial Effects
[0022] Compared with the prior art, the technical solution of the present invention has the following beneficial effects:
[0023] (1) The present invention can monitor blood sugar changes in real time by providing a blood sugar concentration sensor mechanism, an insulin dosing mechanism and a central control unit, and can control the insulin dosing mechanism to automatically dosing according to the blood sugar concentration data, which is safe, convenient and highly operable;
[0024] (2) The present invention sets up a parallel capacitor group including several capacitors, the dielectric of the capacitor is a PVA-PEG-MoS2 mixed gel, and glucose oxidase reacts with interstitial fluid to generate hydrogen peroxide, which oxidizes MoS2 to generate MoO3, reducing the doping amount of MoS2 in the dielectric, thereby changing the dielectric constant of the dielectric, thereby changing the capacitance of the capacitor, and being able to obtain real-time blood glucose concentration through capacitance changes and real-time pulse width changes of the central control unit chip, thereby achieving the function of continuously monitoring blood glucose and controlling drug administration; the present invention has reasonable design, simple structure, convenient operation and strong practicality. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is a simplified diagram of the structure of the device according to an embodiment of the present invention;
[0026] Figures 2-3 This is a schematic diagram of a microfluidic chip according to an embodiment of the present invention;
[0027] Figure 4 A schematic diagram of a single capacitor in a parallel capacitor group according to an embodiment of the present invention;
[0028] Figure 5 This is a schematic diagram of a parallel capacitor group embedded in a microfluidic chip according to an embodiment of the present invention;
[0029] Figure 6 This is a drug administration control flow chart of an embodiment of the present invention;
[0030] The symbols in the accompanying drawings are:
[0031] 1. Shell; 2. Interstitial fluid injection channel; 3. Glucose oxidase injection channel; 4. Pressing tablet; 5. Microfluidic chip; 6. Bottom plate; 7. Microneedle; 8. Parallel capacitor group; 9. Mixing pool; 10. Elastic diaphragm; 11. Electromagnet; 12. Circuit board; 13. Capacitor lead; 14. Interstitial fluid and glucose oxidase flow channel; 15. Parallel capacitor group channel. DETAILED DESCRIPTION
[0032] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] Example 1
[0034] An embodiment of the present invention provides a blood glucose monitoring and drug administration control device based on parallel capacitors, including an interstitial fluid collection microneedle, an interstitial fluid injection channel, a glucose oxidase injection channel, a glucose oxidase storage tank, a parallel capacitor group, an insulin administration mechanism and a central control unit.
[0035] Among them, the parallel capacitor group includes a connecting pipe and several parallel capacitors, the dielectric inside the capacitor is doped with MoS2 nanosheets, the capacitor is provided with a liquid inlet end and a liquid outlet end, and the connecting pipe connects the liquid inlet ends and liquid outlet ends of several capacitors in series in sequence.
[0036] In this embodiment, the dielectric is an electrolytic paper impregnated with a MoS2 gel, and the preparation method is: a MoS2 nanosheet dispersion, polyethylene glycol and polyvinyl alcohol are mixed, stirred and dried at room temperature until a colloid is formed to obtain a PVA-PEG-MoS2 mixed gel, and the electrolytic paper is impregnated in the mixed gel to obtain a dielectric; the mass percentage concentration of the MoS2 nanosheets in the mixed gel is not less than 2%.
[0037] The insulin drug delivery mechanism includes an insulin reservoir, an insulin input channel, a drug delivery power device and a drug delivery microneedle. The insulin reservoir, the insulin input channel and the drug delivery microneedle are connected in sequence. The drug delivery power device is arranged on the insulin input channel and provides drug delivery power under the control of the central control unit.
[0038] The inlet end of the interstitial fluid injection channel is connected to the interstitial fluid collection microneedle, and the outlet end is connected to the inlet of the mixing pool; the inlet end of the glucose oxidase injection channel is connected to the glucose oxidase storage tank, and the outlet end is connected to the inlet of the mixing pool. The outlet of the mixing pool is connected to the entrance of the connecting pipe. A sampling power device is arranged in the mixing pool, and the power device provides power for the flow of interstitial fluid and glucose oxidase under the control of the central control unit. The interstitial fluid inside the interstitial fluid injection channel and the glucose oxidase inside the glucose oxidase injection channel first enter the mixing pool for mixing, and then flow into each capacitor in turn through the connecting pipe and contact with the dielectric in the capacitor. After the glucose oxidase is mixed with the interstitial fluid, it reacts to generate hydrogen peroxide, and the hydrogen peroxide oxidizes the MoS2 doped with the dielectric in the capacitor to generate MoO3, which reduces the doping amount of MoS2 in the dielectric, thereby changing the dielectric constant of the dielectric, thereby causing a change in the capacitance of the capacitor.
[0039] The central control unit is connected to the parallel capacitor group and the insulin delivery mechanism, continuously monitors the total capacitance change of the parallel capacitor group, obtains the real-time pulse width change of the central control unit chip according to the real-time total capacitance change, and then obtains the real-time blood glucose concentration, and controls the insulin delivery mechanism to automatically deliver the drug according to the real-time blood glucose concentration.
[0040] The central control unit can monitor the remaining amount of glucose oxidase in the glucose oxidase reservoir and the remaining amount of insulin in the insulin reservoir, and feed back to the client through the Bluetooth transmission module.
[0041] Example 2
[0042] This embodiment specifically describes the structure of Embodiment 1:
[0043] Reference Figures 1 to 5 In this embodiment, a microfluidic chip 5 is included, and interstitial fluid injection channel 2, glucose oxidase injection channel 3, mixing pool 9 and insulin input channel (not shown in the figure) are all arranged on the microfluidic chip 5, and the microfluidic chip 5 is also provided with an "S"-shaped parallel capacitor group channel, and the parallel capacitor group 8 is arranged in the "S"-shaped channel. The central control unit includes a 555 chip, and the 555 chip is arranged on the microfluidic chip 5.
[0044] In this embodiment, the drug delivery power device is a microperistaltic pump, the insulin reservoir is arranged outside the microfluidic chip 5, the drug delivery microneedle and the interstitial fluid collection microneedle are distributed under the microfluidic chip 5, the drug delivery microneedle is connected to the insulin input channel, and the interstitial fluid collection microneedle is connected to the interstitial fluid injection channel 2.
[0045] In this embodiment, the power device for driving the flow of interstitial fluid and glucose oxidase includes a pressing sheet 4, an electromagnet 11 and an elastic diaphragm 10, the pressing sheet 4 is fixed on the microfluidic chip 5, a through hole is set in the middle of the pressing sheet 4, the elastic diaphragm 10 is set in the through hole and is an integral structure with the pressing sheet 4, iron powder is set in the elastic diaphragm 10, and the electromagnet 11 is fixed above the elastic diaphragm 10. The interstitial fluid injection channel 2 and the glucose oxidase injection channel 3 are respectively provided with a one-way valve. When the electromagnet 11 is energized, it can attract or repel the elastic diaphragm 10 with built-in iron powder, and then the elastic diaphragm 10 moves up and down. When the elastic diaphragm 10 is sucked up, it can drive the interstitial fluid collection microneedle to extract the interstitial fluid. When the elastic diaphragm 10 is pressed down, it can drive the liquid in the mixing pool 9 to flow to the parallel capacitor group 8, thereby realizing the power driving effect.
[0046] Example 3
[0047] This embodiment provides a blood glucose monitoring and drug administration control method based on parallel capacitors, which is completed based on the device described in Example 1. The control method includes:
[0048] Step 1: Start the driving device, the interstitial fluid collection microneedle draws interstitial fluid from the skin and enters the interstitial fluid injection channel, and at the same time, the glucose oxidase in the glucose oxidase reservoir enters the glucose oxidase injection channel.
[0049] Step 2, interstitial fluid and glucose oxidase enter the parallel capacitor group, flow into each parallel capacitor in turn through the connecting pipe, and come into contact with the dielectric doped with MoS2 nanosheets in the capacitor. After the glucose oxidase mixes with the interstitial fluid, it reacts to generate hydrogen peroxide, and the hydrogen peroxide oxidizes MoS2 to generate MoO3, so that the doping amount of MoS2 in the dielectric decreases, and the dielectric constant of the dielectric changes, thereby changing the capacitance of the capacitor.
[0050] Step 3: The central control unit monitors the total capacitance change of the parallel capacitor group in real time, and obtains the real-time blood glucose concentration according to the real-time pulse width change of the central control unit chip.
[0051] The relationship between real-time blood sugar concentration and real-time pulse width of the central control unit chip is:
[0052]
[0053] Among them, Δt w is the real-time pulse width variation of the central control unit chip; n k is the number of capacitors consumed after the kth detection; n k-1 is the number of capacitors consumed after k-1 tests; S is the effective relative area between capacitor electrodes, which is a constant; d is the effective spacing between capacitor electrodes, which is a constant; C max is the initial capacitance value of a single capacitor; C minis the capacitance value of a single capacitor after MoS2 is depleted; K is the dielectric-mass fraction proportional coefficient of MoS2 in the dielectric; μ is the consumption coefficient between blood glucose and MoS2 in the catalytic process, which is a constant when the temperature is constant; V is the volume of interstitial fluid extracted each time; R is the equivalent resistance of the central control unit chip, which is a constant.
[0054] Step 4: When the blood glucose concentration is monitored to be greater than the specified value, the central control unit controls the drug delivery power device to start, and the insulin in the insulin reservoir is automatically delivered through the insulin input channel and the drug delivery microneedle.
[0055] The present invention can monitor blood sugar changes in real time by arranging a blood sugar concentration sensing mechanism, an insulin administration mechanism and a central control unit, and control the insulin administration mechanism to automatically administer the drug according to the blood sugar concentration data. The parallel capacitor group includes a plurality of capacitors in parallel, the dielectric of the capacitor is a PVA-PEG-MoS2 mixed gel, glucose oxidase reacts with the interstitial fluid to generate hydrogen peroxide, and hydrogen peroxide oxidizes MoS2 to generate MoO3, reducing the doping amount of MoS2 in the dielectric, thereby changing the dielectric constant of the dielectric, thereby changing the capacitance of the capacitor, and being able to obtain real-time blood sugar concentration through capacitance changes, achieving the effect of continuously monitoring blood sugar and controlling administration. The present invention has reasonable design, simple structure, convenient operation and strong practicality.
[0056] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by a technician familiar with the technical field within the technical scope disclosed by the present invention should be covered within the protection scope of the present invention.
Claims
1. A blood glucose monitoring and drug administration control device based on parallel capacitors, characterized in that: It includes an interstitial fluid collection microneedle, an interstitial fluid injection channel, a glucose oxidase injection channel, a parallel capacitor group, an insulin delivery mechanism and a central control unit; The parallel capacitor group includes a connecting pipe and a plurality of parallel capacitors, the dielectric inside the capacitor is doped with MoS2 nanosheets, the capacitor is provided with a liquid inlet end and a liquid outlet end, and the connecting pipe connects the liquid inlet ends and the liquid outlet ends of the plurality of capacitors in series in sequence; The interstitial fluid injection channel is connected to the interstitial fluid collection microneedle on one hand, and is communicated with the inlet of the connecting pipe on the other hand, and the glucose oxidase injection channel is communicated with the inlet of the connecting pipe; the interstitial fluid in the interstitial fluid injection channel and the glucose oxidase in the glucose oxidase injection channel flow into each capacitor in sequence through the connecting pipe and contact the dielectric in the capacitor; The central control unit is connected to the parallel capacitor group and the insulin delivery mechanism, continuously monitors the real-time total capacitance change of the parallel capacitor group, obtains the real-time pulse width change of the central control unit chip according to the real-time total capacitance change, and then obtains the real-time blood glucose concentration, and controls the insulin delivery mechanism to automatically deliver the drug according to the real-time blood glucose concentration.
2. The blood glucose monitoring and drug administration control device based on parallel capacitors according to claim 1, characterized in that: The insulin delivery mechanism comprises an insulin storage tank, an insulin input channel, a delivery power device and a delivery microneedle; The insulin storage tank, the insulin input channel and the drug delivery microneedle are connected in sequence, and the drug delivery power device is arranged on the insulin input channel to provide drug delivery power under the control of the central control unit.
3. The blood glucose monitoring and drug administration control device based on parallel capacitors according to claim 1, characterized in that: The dielectric is electrolytic paper impregnated with MoS2 gel, and the preparation method is as follows: The MoS2 nanosheet dispersion, polyethylene glycol and polyvinyl alcohol are mixed, stirred and dried at room temperature to form a PVA-PEG-MoS2 mixed gel, and the electrolytic paper is immersed in the mixed gel to obtain a dielectric; The mass percentage concentration of the MoS2 nanosheets in the mixed gel is not less than 2%.
4. The blood glucose monitoring and drug administration control device based on parallel capacitors according to claim 1, characterized in that: A mixing tank is also provided; The liquid outlet ends of the interstitial fluid injection channel and the glucose oxidase injection channel are respectively connected to the liquid inlet of the mixing tank, and the liquid outlet of the mixing tank is connected to the inlet of the connecting pipe. The interstitial fluid inside the interstitial fluid injection channel and the glucose oxidase inside the glucose oxidase injection channel first enter the mixing tank for mixing, and then flow into each capacitor in turn through the connecting pipe.
5. The blood glucose monitoring and drug administration control device based on parallel capacitors according to claim 4, characterized in that: A sampling power device is also provided, which provides power for the flow of interstitial fluid and glucose oxidase under the control of the central control unit.
6. The blood glucose monitoring and drug administration control device based on parallel capacitors according to claim 1, characterized in that: A glucose oxidase reservoir is also provided, and the glucose oxidase reservoir is connected to the glucose oxidase injection channel.
7. A blood glucose monitoring and drug administration control method based on parallel capacitors, characterized in that: Based on the device according to any one of claims 1 to 6, the control method includes: S1, start the driving device, the interstitial fluid collection microneedle draws interstitial fluid from the skin and enters the interstitial fluid injection channel, and at the same time, the glucose oxidase in the glucose oxidase reservoir enters the glucose oxidase injection channel; S2, interstitial fluid and glucose oxidase enter the parallel capacitor group, flow into each parallel capacitor in turn through the connecting pipe, and come into contact with the dielectric doped with MoS2 nanosheets in the capacitor, the dielectric constant of the dielectric changes, and thus the capacitance of the capacitor changes; S3, the central control unit monitors the total capacitance change of the parallel capacitor group in real time, obtains the real-time pulse width change of the central control unit chip according to the real-time total capacitance change, and then obtains the real-time blood glucose concentration; S4. When the real-time blood glucose concentration is monitored to be greater than the specified value, the central control unit controls the drug delivery power device to start, and the insulin in the insulin reservoir is automatically delivered through the insulin input channel and the drug delivery microneedle.
8. The blood glucose monitoring and drug administration control method based on parallel capacitors according to claim 7, characterized in that: In the S2, glucose oxidase reacts with the interstitial fluid to generate hydrogen peroxide, and the hydrogen peroxide oxidizes MoS2 to generate MoO3, which reduces the doping amount of MoS2 in the dielectric, thereby reducing the dielectric constant of the dielectric, thereby changing the capacitance of the capacitor.
9. The blood glucose monitoring and drug administration control method based on parallel capacitors according to claim 7, characterized in that: In S3, the relationship between the real-time blood glucose concentration and the real-time pulse width change of the central control unit chip is: Among them, Δt w is the real-time pulse width variation of the central control unit chip; n k is the number of capacitors consumed after the kth detection; n k-1 is the number of capacitors consumed after k-1 tests; S is the effective relative area between capacitor electrodes, which is a constant; d is the effective spacing between capacitor electrodes, which is a constant; C max is the initial capacitance value of a single capacitor; C min is the capacitance value of a single capacitor after MoS2 is depleted; K is the dielectric-mass fraction proportional coefficient of MoS2 in the dielectric; μ is the consumption coefficient between blood glucose and MoS2 in the catalytic process, which is a constant when the temperature is constant; V is the volume of interstitial fluid extracted each time; R is the equivalent resistance of the central control unit chip, which is a constant.
10. The blood glucose monitoring and drug administration control method based on parallel capacitors according to claim 7, characterized in that: The central control unit can monitor the remaining amount of glucose oxidase in the glucose oxidase reservoir and the remaining amount of insulin in the insulin reservoir, and feed back to the client through the Bluetooth transmission module.
Citation Information
Cited By
Diagnosis and treatment integrated microneedle array device and preparation method thereof
CN122499424A
